Live Breaking News & Updates on Analysts at emkay global financial service

Stay informed with the latest breaking news from Analysts at emkay global financial service on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Analysts at emkay global financial service and stay connected to the pulse of your community

Lupin rises on settling dispute with Gavis and Novel; gains 5% in four days

Shares of Lupin were trading 2.5 per cent higher at Rs 985 on the BSE on Thursday after the pharmaceutical company settled a dispute with Gavis Pharma and Novel Laboratories. The stock was trading higher for the fourth straight day, up 5 per cent during the same period.
On Wednesday, Lupin announced in a BSE filing that its dispute with the sellers in the Gavis/Novel transaction has been resolved amicably to the satisfaction of all parties.
In the past one month, the stock has outperformed the market by gaining 11 per cent, as compared to a 6.6-per cent rise in the S&P BSE Sensex. However, in the past three months, it has underperformed the indices by falling 5 per cent, as against a 20-per cent rally in the benchmark index. The stock hit a 52-week high of Rs 1,122 on September 18, 2020.

United-states , American , Gavis-pharma , Analysts-at-emkay-global-financial-service , Concord-biotech , Prograf-capsules , Astellas-pharma , Emkay-global-financial-service , ஒன்றுபட்டது-மாநிலங்களில் , அமெரிக்கன் , ஆய்வாளர்கள்-இல்-எம்காய்-உலகளாவிய-நிதி-சேவை , ஒத்திசைவு-பயோடெக்